Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with Neoadjuvant Chemotherapy in Inflammatory Breast Cancer
NCT03742986Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- May 2019
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in inflammatory breast cancer (IBC), sponsored by NYU Langone Health. Started May 2019; status: completed.
02
Drugs
03
Conditions
inflammatory breast cancer (IBC)
Beyond the preview
Go deeper on NCT03742986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03742986.